Research identifies, exploits vulnerability in certain high-risk cancers
In a study recently published in Cancer Research, a journal of the American Association for Cancer Research, a team of researchers led by C. Patrick Reynolds, M.D., Ph.D., director for the Texas Tech University Health Sciences Center (TTUHSC) School of Medicine Cancer Center, sought to expand upon his lab's previous research that showed ALT tumors identified by a biomarker known as C-circles share a common biology that confers vulnerabilities to be exploited for cancer therapy. (Source: World Pharma News)
Source: World Pharma News - August 10, 2022 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Recent cancer diagnosis or treatment lowers COVID-19 vaccine effectiveness, UK Covid Vaccine Research Hub
This new study, published in the European Journal of Cancer, set out to evaluate the effectiveness of the third vaccine dose in over 360,000 people with cancer, compared to the general population, using data from Public Health England ' s national cancer dataset between December 2020 to December 2021. Overall, the researchers found that third vaccines doses were less effective in people with cancer than in the general population and concluded that many people with cancer remain at increased risk of infection, even after three doses. Lower vaccine effectiveness was found to be associated with: a cancer diagnosis in the pr...
Source: Current Awareness Service for Health (CASH) - August 2, 2022 Category: Consumer Health News Source Type: news

Novasenta Completes $40 million Series A to Advance Novel Cancer Therapeutics
PITTSBURGH, July 29, 2022 -- (Healthcare Sales & Marketing Network) -- Novasenta Inc., a startup biotechnology company focused on the discovery and validation of novel targets to develop cancer therapies, today announced the completion of $40 million in S... Biopharmaceuticals, Oncology, Venture Capital Novasenta, tumor microenvironment (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 29, 2022 Category: Pharmaceuticals Source Type: news

Nigeria: Meet Moji Animasaun, Former Radiologist Building a Cancer Supercentre in Nigeria
[Vanguard] With a view to raising the funds urgently required to build a comprehensive cancer therapy centre, St. Cyril's Cancer Centre, a nongovernmental organisation, NGO has launched an initiative set to involve one million donors. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - July 28, 2022 Category: African Health Source Type: news

Clarity completes recruitment for prostate cancer trial
Australian radiopharmaceutical developer Clarity Pharmaceuticals has complete...Read more on AuntMinnie.comRelated Reading: Clarity secures IND from FDA for radiotracer for prostate cancer Clarity treats first patient in COBRA trial Clarity launching trial for prostate cancer therapy Clarity hits milestone in study of radiopharmaceutical (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 20, 2022 Category: Radiology Source Type: news

Could an Experimental Cancer Drug Help Treat Spinal Injury?
MONDAY, July 18, 2022 -- A drug in development as a cancer therapy may also help the body regenerate damaged nerves after spinal injuries, new research suggests. Scientists at the University of Birmingham in the United Kingdom report that they used... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 18, 2022 Category: General Medicine Source Type: news

Research shows investigational drug fosters nerve repair after injury
Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of damaged nerves after spinal trauma. The research, published in Clinical and Translational Medicine, used cell and animal models to demonstrate that when taken orally the candidate drug, known as AZD1390, can block the response to DNA damage in nerve cells and promote regeneration of damaged nerves, so restoring sensory and motor function after spinal injury. (Source: World Pharma News)
Source: World Pharma News - July 12, 2022 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

New Patient Tumor Cell Models Rapidly Predict Cancer Therapy Outcomes
A new benchtop microfluidic device generates patient-derived tumor micro-organospheres that allow for real-time cancer therapy decisions. (Source: The Scientist)
Source: The Scientist - July 11, 2022 Category: Science Tags: Sponsored Article Source Type: news

Scientists pinpoint new brain target for antinausea drugs
Whether we’ve got the flu or have had too much to drink, most of us have experienced nausea. Unlike other universal sensations such as hunger and thirst, however, scientists still don’t understand the biology behind the feeling—or how to stop it. A new study in mice identifies a possible key player: specialized brain cells that communicate with the gut to turn off the feeling of nausea. It’s an “elegant” study, says Nancy Thornberry, CEO of Kallyope, a biotechnology company focused on the interplay between the gut and the brain. Further research is needed to translate the finding into antinausea therapies...
Source: ScienceNOW - June 29, 2022 Category: Science Source Type: news

Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology
Bayer AG announced today the opening of its new Research and Innovation Center at Kendall Square in Boston-Cambridge, Massachusetts (U.S.A.), expanding further the company's footprint into one of the world’s most innovative pharmaceutical research and development locations. Representing a total $140M USD investment into the area, Bayer's 62,100-square-foot building houses a new center of precision molecular oncology research equipped with state-of-the-art laboratories and offices for the development of novel targeted cancer therapies for patients. (Source: World Pharma News)
Source: World Pharma News - June 29, 2022 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news

Q & A: Wichita's role in bringing emerging cancer treatment to the region
Dr. Shaker Dakhil and the Cancer Center of Kansas has played a pivotal role in bringing new cancer therapies to Kansas. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - June 24, 2022 Category: American Health Authors: Shelby Kellerman Source Type: news

Single-cell analysis reveals clues about promising cancer therapy
A team of researchers has uncovered some critical clues about why a significant number of patients relapse from CAR T therapy for blood cancer. (Source: Yale Science and Health News)
Source: Yale Science and Health News - June 22, 2022 Category: Universities & Medical Training Source Type: news

Fastest-growing public companies: Revenue spikes for Waltham cancer drug firm
Syndax Pharmaceuticals has toiled for years toward finding cancer therapies that can improve the lives of patients. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 17, 2022 Category: Pharmaceuticals Authors: Grant Welker Source Type: news

SNMMI Image of the Year predicts poor outcomes after heart attack
PET imaging that reveals poor outcomes in patients after a heart attack ha...Read more on AuntMinnie.comRelated Reading: Dual-tracer PET/CT shows promise in cancer imaging PET imaging lays foundation for new cancer therapies PET tracer shows promise for diagnosing breast cancer Animal study suggests Ga-68 PET FAPI can detect lung fibrosis (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 15, 2022 Category: Radiology Source Type: news

For Exelixis, collaboration is essential for improving outcomes for patients with cancer
A continuing challenge in cancer therapy is effectively killing cancer cells while protecting healthy tissue. Overcoming this obstacle requires the ability to identify and target cancer-related pathways without disturbing normal cell function. Exelixis was founded in 1994 with an initial focus on turning deep biologic insights into novel cancer therapies that have the potential to improve patient outcomes. This focus has allowed us to establish a successful commercial franchise around our lead… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 15, 2022 Category: Pharmaceuticals Authors: Michael M. Morrissey, Ph.D. Source Type: news